CLYM vs PSA · $85.8M cap vs rev $1.23B
Climb Bio Inc (CLYM) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Climb Bio Inc (CLYM) is a biotechnology company listed on US.
PSA (PSA) common stock.
CLYM does not have a complete income-statement cache yet.
Latest reported PSA revenue for 2026-06-30 was $1.23B. Net income was $500.0M. Revenue was up 1.2% from 2026-03-31 to 2026-06-30. PSA currently screens at market cap $0.
CLYM currently screens at market cap $85.8M. PSA currently screens at market cap $0.
Not investment advice. Open the CLYM and PSA stock pages for the full models.
Not investment advice.